Immunotherapy studies open for triple-negative breast cancer

January 24, 2019 Providence News Team

Emerging research is finding that immunotherapy may extend survival for some women with triple-negative breast cancer. Providence Cancer Institute, a leader in immunotherapy research, is actively investigating options for this aggressive cancer. Studies are open now for women with metastatic and non-metastatic TNBC, including these featured studies:

An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan (IMMU-132) versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments (ASCENT)

Sacituzumab govitecan is an antibody-drug conjugate that targets a glycoprotein expressed in more than 90 percent of triple-negative breast cancers. In 2016, the FDA granted it breakthrough therapy designation for metastatic TNBC following at least two prior treatments, and it is currently under priority review for licensing. Read about previous studies of this therapy in OncLive.

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Pembrolizumab (Keytruda) is a monoclonal antibody that is FDA approved for several other types of cancer. It works by interfering with PD-1, a protective mechanism on the surface of cancer cells. This trial is studying how well pembrolizumab works in treating triple-negative breast cancer.

For more information about these studies, or to enroll a patient, call our Clinical Research office at 503-215-2614.

See more breast cancer studies

More than 20 research studies investigating a broad spectrum of breast cancer therapies and interventions are currently open at Providence Cancer Institute, including several for triple-negative breast cancer.

We offer studies aimed at improving cure rates, quality of life and survival for both early-stage and metastatic breast cancer patients. These studies range from small phase I clinical trials to larger international studies, including studies from the National Cancer Institute, our own NCI Community Oncology Research Program (the Pacific Cancer Research Consortium), and pharmaceutical industry partners. Our own investigator-initiated research studies, available exclusively at Providence Cancer Institute, focus on novel approaches that harness the immune system to treat cancer.

New research studies are added frequently. Please visit our website to see all breast cancer studies currently open at Providence Cancer Institute.

A team of breast cancer specialists

The research team at the Earle A. Chiles Research Institute at Providence Cancer Institute includes oncologists who specialize exclusively in breast cancer, as well as breast-cancer-focused research nurses, laboratory scientists, data coordinators and lab assistants. Every person on this team is passionate about providing the best possible care and the best available study options for patients with breast cancer.

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.
More Content by Providence News Team

Welcome to your journey for creating a healthier you

Immunotherapy studies open for triple-negative breast cancer

See more breast cancer studies

A team of breast cancer specialists

About the Author

Previous Article

Next Article

Immunotherapy studies open for triple-negative breast cancer

See more breast cancer studies

A team of breast cancer specialists

About the Author

Previous Article

Next Article

Other content in this Stream

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.

Providence Cancer Institute in partnership with AIM at Melanoma present a free online event designed to educate and empower patients and care partners affected by melanoma.

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Dr. Allie Grossmann’s new lab at Earle A. Chiles Research Institute is focused on understanding how tumors communicate with their environment, grow, survive and spread.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

A new medication may help people with KRAS G12C-mutant non-small cell lung cancer. Read about the study and a trial evaluating an immunotherapy for treating head and neck squamous cell carcinoma.

Cancer survivor Mark Williams chats with Dr. Brendan Curti about

What motivates the co-captains of the FINISHCANCER caregiver team to commit their time to running this remarkable relay? Read what they say about preparing for the race and what inspires them to run.

Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.

A study designed to treat recurrent epithelial ovarian cancer looks at an antibody drug conjugate, and a second study for people with advanced breast cancer evaluates a drug that degrades estrogen rec

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

June is National Cancer Survivor Month, but we honor people with cancer, no matter where they are on their journey, every day of the year. Find out about the survivorship program at Providence Cancer

Providence Cancer Institute presented a free virtual education event about MRI-guided radiation therapy and how it is used to treat pancreatic cancer.

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.

The radiation oncology team at Joe Arrington Cancer Center is awarded APEx Accreditation for excellent care.

Explore three innovative studies targeting uveal melanoma, melanoma and head and neck squamous cell carcinoma. Learn why these studies offer hope for more effective cancer treatments.

Patient Navigators provide a wealth of information and support to patients and families at all three Providence oncology locations: Lacey, Centralia and Aberdeen.